Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday. The brokerage currently has a $11.00 price target on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 18.28% from the stock’s current price.

According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

Several other analysts have also commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price objective on shares of Karyopharm Therapeutics in a research report on Monday, May 15th. Wedbush reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, April 5th. Robert W. Baird reiterated an “outperform” rating and issued a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday, April 6th. Jefferies Group LLC reiterated a “buy” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research note on Monday, March 13th. Finally, ValuEngine downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 25th. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $14.56.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 1.90% during midday trading on Thursday, reaching $9.30. 111,806 shares of the company’s stock traded hands. Karyopharm Therapeutics has a 12 month low of $6.27 and a 12 month high of $14.63. The stock has a 50 day moving average of $9.29 and a 200-day moving average of $10.20. The stock’s market cap is $438.20 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.04. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.02 million. Karyopharm Therapeutics had a negative return on equity of 72.41% and a negative net margin of 50,646.40%. During the same period in the prior year, the firm posted ($0.75) EPS. On average, equities research analysts forecast that Karyopharm Therapeutics will post ($2.68) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/07/09/karyopharm-therapeutics-inc-nasdaqkpti-stock-rating-upgraded-by-zacks-investment-research.html.

A number of institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP boosted its position in shares of Karyopharm Therapeutics by 0.9% in the first quarter. Wellington Management Group LLP now owns 5,780,553 shares of the company’s stock valued at $74,223,000 after buying an additional 54,137 shares in the last quarter. Palo Alto Investors LLC raised its stake in shares of Karyopharm Therapeutics by 6.4% in the first quarter. Palo Alto Investors LLC now owns 3,406,475 shares of the company’s stock valued at $43,739,000 after buying an additional 206,079 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Karyopharm Therapeutics by 9.8% in the first quarter. Vanguard Group Inc. now owns 1,236,762 shares of the company’s stock valued at $15,880,000 after buying an additional 110,093 shares during the last quarter. Tekla Capital Management LLC raised its stake in shares of Karyopharm Therapeutics by 21.0% in the first quarter. Tekla Capital Management LLC now owns 605,224 shares of the company’s stock valued at $7,771,000 after buying an additional 104,900 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Karyopharm Therapeutics by 25.8% in the first quarter. JPMorgan Chase & Co. now owns 518,610 shares of the company’s stock valued at $6,660,000 after buying an additional 106,234 shares during the last quarter. 57.11% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.